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Abstract. Background: Solid tumours have worse prognosis
when associated with thrombocytosis. Our study assessed the
prognostic value of thrombocytosis, and its relation with
smoking habits in lung cancer. Patients and Methods: A total
of 398 patients were operated on then divided into two
groups, those with normal platelet counts (n=312), and those
with thrombocytosis (n=86); 348 out of 398 patients had
data for smoking habits (99 non-smokers, 249 smokers).
Results: The frequency of thrombocytosis was 18.6%, 19.3%,
27.5 and 28.6% in patients with tumor stages I to IV,
respectively. Thrombocytosis appeared most frequently in
patients with squamous cell lung cancer, and among
smokers. The overall 5-year survival was worse in patients
with thrombocytosis (p<0.001). By uni- and multivariate
analyses, platelet count, and T and N status were found to
be independent prognostic factors. Conclusion: Our study
indicates that the presence of perioperative thrombocytosis
in patients undergoing surgery should be considered as an
independent prognostic factor of poor survival, and should
be taken into account in regard to therapy.
Survival after lung cancer resection is mainly dependent on
tumor stage (1), but other factors are also known to influence
it. In resected stage I lung cancer cases, the tumor size,
smoking index, and number of dissected mediastinal lymph
nodes are all prognostic factors for overall and disease-free
survival (2). Poor tumor differentiation is a risk factor for
recurrence and carries an unfavorable prognosis (3). The
impact of smoking on survival is widely discussed. Smoking
was significantly predictive of a poor prognosis after resection
of different stages of lung cancer (4) and in stage I
adenocarcinomas (5), but there was no difference in terms of
survival between smokers and non-smokers with advanced
non-small cell lung cancers (6). Thrombocytosis has been
proven to have a fundamental impact on survival in advanced
cervical (7) and renal cell cancer (8). Unfavorable outcome in
association with thrombocytosis has been described in patients
with esophageal (9), gastric (10) and soft tissue cancer (11).
Currently only a few articles exist, discussing the impact of
thrombocytosis on lung cancer survival, or in resected cases.
Previous studies have reported mainly unfavorable (12, 14, 16-
18) or no impact (19) on survival of a high thrombocyte count
among patients with non-small cell lung cancer. In several
studies, thrombocytosis was detected as an independent
prognostic factor (14, 16, 18). In this retrospective study, we
evaluated the incidence and potential impact of thrombocytosis
on outcome, also analyzing the smoking habits of patients who
underwent lung cancer resection. 
Patients and Methods
The study was conducted in full accordance with the institutional
regulations and all the patients gave their written informed consent
prior to participation in the surgery.
Study population. Patients operated on for lung cancer at the
Department of Surgery in a 5-year period between January 2003 and
December 2007 were eligible for analysis in this study. For each
patient, the treatment plan was designed by a multidisciplinary
onco-team. 
Surgical, histological and staging procedures. Resections performed
for the 398 lung cancer cases were as follows: 124 pneumonectomies,
214 lobectomies, 6 bi-lobectomies, 27 atypical resections and 27
explorations. In all cases systematic mediastinal lymphadenectomy
was performed. Preoperative staging examinations routinely included
a chest X-ray, chest CT, bone scintigraphy, brain CT, abdominal
ultrasound, bronchoscopy and spirometry based on the conventional
protocol. The primary tumor and the mediastinal lymph nodes were
histologically analyzed by the use of a standard pathological local
protocol and AJCC TNM classification, sixth edition (1). Patient files
were reviewed, and relevant data were collected. 
Definition of thrombocytosis and smoking habits. The platelet counts
were assessed three times during the perioperative period: just
before surgery, and on the first and seventh postoperative days. If
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all three samples were evaluated to be higher than 400×103/μl, in
agreement with other studies (7, 10, 12, 14, 15), thrombocytosis was
diagnosed. Based on this data, the 398 patients were divided into
two groups as to whether they had normal platelet counts or
thrombocytosis in the perioperative period. Among all patients, two
subgroups were formed regarding their smoking habits. A total of
348 out of the 398 patients had smoking habit data. Non-smokers
either never smoked or smoked little in the past, but stopped 10
years or more prior to lung surgery, and smokers smoked at the time
of surgery or had smoked in the past 10 years. 
Statistical analysis. All analyses were carried out using SPSS
version 20.0 for Windows (SPSS Inc., Chicago, IL, USA). The
associations between thrombocytosis and clinical factors (stage,
histology, gender) were evaluated with the chi-square test, and the
correlation between thrombocytosis and age were tested with
independent samples t-test. Overall survival was analyzed by
Kaplan-Meier analysis. The univariate- and multivariate analysis of
the platelet count, T status, N status, stage and their impact on
survival were evaluated with Cox regression test.
Results
Patients’ characteristics. Three-hundred and ninety eight
consecutive patients with primary lung cancer were included
in the study. There were 293 (73.6%) males and 105 (26.4%)
females, with a mean age (±SD) of 58.3 (±8.99) (range 36-
79) years. Most of the patients had stage I cancer (47.2%).
The performance status of the patients was good (ECOG 0
and 1, 44% and 56%, respectively). The histological type was
squamous cell carcinoma in 175 (44%), adenocarcinoma in
163 (41%) and large cell, small cell lung cancer and carcinoid
in 33 (8.3%), 13 (3.3%) and 14 (3.5%) cases, respectively. 
Association of thrombocytosis and smoking habits with
clinicopathological characteristics. Out of the 398 patients
operated on for lung cancer, 86 (21.6%) were determined to have
thrombocytosis. The incidence of thrombocytosis gradually
elevated according to increesing cancer stage. In stage I, 18.6%
of cases had thrombocytosis, in stage II, III and IV 19.3%,
27.8% and 28.6%, had thrombocytosis respectively. There were
no significant associations between stage (p=0.074), histology
(p=0.078), age (p=0.089), gender (p=0.516) and platelet count
values. Only 348 out of the 398 patients had data concerning
their smoking habits: 260 of these patients (75%) were male and
88 patients (25%) were female. A total of 249 (71.6%) out of the
348 patients were smokers and 99 (28.4%) were non-smokers.
The distribution of thrombocytosis and smoking habit according
to the pathological stage of all resected lung carcinomas is
described in Table I; no significant differences were found.
Thrombocytosis was significantly more frequent in smokers
(26.1%) than in non-smokers (10.1%) (p=0.001) (Table II). This
correlation was detected in the squamous cell subgroup
(p=0.004), in contrast with patients with non-squamous cell
histologies (p=0.082). The frequency of smokers was also higher
in patients who suffered from squamous cell cancer than those
with other histology. The incidence of thrombocytosis was also
higher in the squamous cell subgroup, in which 94.9% of
patients with thrombocytosis were smokers. The data for
smoking habits and thrombocytosis in the squamous cell and
other histological subtypes are detailed in Table III. 
Association of thrombocytosis and smoking habit with
outcome of patients. The median follow-up time of the entire
population was 62.0 (range=1-103) months. The overall
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Table I. Distribution of thrombocytosis and smoking habits according to the pathological stage in the entire population.
All patients, Patients with known 
N=398 smoking history, N=348
Stage All patients PLT <400×103/μl PLT >400×103/μl Non-smokers Smokers
n=398 n=312 n=86 n=99 n=249
IA 18.6% 20% 14% 21% 16%
IB 28.6% 29.2% 26.7% 31% 28.9%
IIA 1.8% 1.9% 1.2% 1% 2%
IIB 20.4% 20.8% 18.6% 18% 19.7%
IIIA 19.8% 17.9% 26.7% 15% 22.1%
IIIB 7.3% 7.1% 8.1% 7% 8.4%
IV 3.5% 3.2% 4.7% 6% 2.8%
PLT, Platelet count.
Table II. The association between thrombocytosis and smoking habit
(p=0.001).
Non-smokers Smokers
n=99 n=249
Normal platelet count (<400×103/μl) 89 (89.9%) 184 (73.9%)
Thrombocytosis (>400×103/μl) 10 (10.1%) 65 (26.1%)
survival of the entire population was 31.0 months, and 14.8%
of the patients were still alive after five years of follow-up.
The overall 5-year survival was 35% among patients with
thrombocytosis, and 50.8% among patients with a normal
thrombocyte count (p<0.001). The overall survival time was
63.1 months in the group without and 38 months in the
group with thrombocytosis (p<0.001) (Figure 1). There were
no significant associations between the overall survival and
gender (p=0.392), smoking habit (p=0.724) or histology
(p=0.148). A significant association was detected in the case
of overall survival in the squamous histological subgroup
according to the patient’s platelet count (thrombocytosis vs.
normal) (p<0.001), but such an association was not found in
the other histological subgroups (p=0.916). The survival of
the patients significantly correlated with tumor stage for the
whole study group (p<0.001) and also in the subgroup of
patients with normal platelet counts (p<0.001), but there was
no difference among the patients with thrombocytosis
(p=0.13), presumably because of the relatively small number
of cases (Table IV). By univariate analysis, except histology
(p=0.148), advanced stage of lung cancer (p<0.001), greater
tumor size (p<0.001), lymph node involvement (p<0.001)
and the presence of thrombocytosis (p<0.001) were
significantly associated with a decreased survival. By
multivariate analysis, the presence of thrombocytosis, greater
tumor size and lymph node involvement were all
independent factors related to poorer survival (Table V).
Discussion
The present study demonstrated that an increased platelet
count can help to predict unfavorable outcome in lung
cancer. We observed a strong association not only between
the T and N status and stages, but also between the presence
of thrombocytosis and the 5-year survival of the patients
after surgery. Thrombocytosis was significantly more
frequent among smokers than non-smokers. The novelty of
our study lies in the analysis of a high platelet count as a
potential prognostic marker in relation to the outcome of
lung cancer and on which few data have been published.
Secondary, or reactive thrombocytosis is observed in a
variety of underlying conditions, which may cause either an
acute and transient elevation of platelet count (trauma, major
surgery, acute bleeding) or more sustained thrombocytosis
(infection or neoplasia) in patients. Thrombocytosis has a
prevalence as high as 30% in patients with lung cancer, and
has been associated with extensive and/or metastatic disease
and a worse prognosis. The percentage of patients with
elevated platelet counts was 21.6% among all our resected
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Figure 1. Kaplan-Meier survival curves for patients with lung cancer
patients according to platelet count.
Table III. The distribution of thrombocytosis and smoking habit according to squamous cell and other histological subtypes.
All patients, Patients with known 
N=398 smoking history, N=348
PLT <400×103/μl PLT >400×103/μl Non-smokers Smokers
n=312 n=86 n=99 n=249
Squamous cell lung cancer 130 (74.3%) 45 (25.7%) 35 (21.5%) 128 (78.5%)
Other histology 182 (81.6%) 41 (18.4%) 64 (34.6%) 121 (65.4%)
p-Value (Chi-square test) 0.001 0.007
PLT, Platelet count.
lung cancer cases, the frequency of the incidence was higher
in more advanced stages (18.6% in stage I and 27.5% in
stage III), which is similar to the proportion of
thrombocytosis in the study of Pedersen and Milman (20%
in stage I and 30% in stage IIIA) (12). The study by
Hamilton et al. presented comparable data, as
thrombocytosis occurred in 26% of lung cancer cases (13).
In our study, thrombocytosis appeared most frequently in
squamous cell lung cancer (52%) than in other histological
subtypes. Similar data were presented in the study by
Pedersen and Milman (12). Smoking habit can have an
impact on the type of lung cancer. Nakamura et al. reported
squamous cell cancer as being most frequent among
smokers (4). Among the smokers participating in our study,
the incidence of squamous cell lung cancer was also the
most frequent, in addition, we discovered that
thrombocytosis was significantly more frequent in smokers
than in non-smokers. There was no difference in 5-year
survival between smokers and non-smokers in patients with
normal platelet counts or thrombocytosis. There was no
significant difference in survival between smokers and non-
smokers in advanced lung cancer cases presented by Toh et
al. (6), but Nakamura et al. presented smoking as being
significantly predictive of a poor prognosis after resection
of different stages of lung cancer (4). The impact of
thrombocytosis on the survival was analyzed from different
aspects. Using the current TNM lung cancer classification
(1), there was a significant difference in the survival based
on the stages, using an overall comparison. In our study,
analyzing all patient data or only data for patients with
normal platelet counts, we found the same significant
correlation in survival rates in the different stages. When we
analyzed the survival among patients with thrombocytosis
during the perioperative period, there was no significant
difference in survival among the stages, presumably,
because thrombocytosis resulted in the unfavorable outcome
of the whole group, or because of the relatively small
number of cases. Thus the survival rates among the different
stages in patients with thrombocytosis did not show a wide
range. According to Mountain (1), the five-year survival in
pathological stage IA and IB cases was 67% and 57%, close
to the five-year survival for our patients overall (75 and
59%, respectively). The survival rate was significantly
reduced in patients with preoperative thrombocytosis
according to Pedersen and Hamilton (12), and in the
evaluated patients in the trial of Aoe et al. (14), while in our
study there was also a significant difference in the overall
survival between the high and normal platelet level groups.
Using univariate analysis of the gender, smoking habit,
histology, T status, N status, stage and platelet count, only
the latter four had a significant impact on survival.
Multivariate analysis of the T status, N status and platelet
count showed that all were independent factors for survival.
This finding is in accordance with the results of Pedersen
and Milman (12), and also of Aoe et al. (14) among patients
treated with resection or conservative treatments for lung
cancer. To sum up, thrombocytosis had a significant negative
impact on survival by both uni- and multivariate analyses,
and in the separately evaluated squamous histological
subgroup. Survival after lung resection was remarkably
lower in patients with thrombocytosis during the
perioperative period compared to patients with normal
platelet counts. Thrombocytosis was evidently more
frequent in smokers. In conclusion, the present study has
revealed that thrombocytosis during the perioperative period
in patients undergoing lung cancer resection can be
considered as a potential negative independent factor for
survival, and should be taken into account in the decision
regarding indication for adjuvant therapy.
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